Marker Therapeutics Management
Management criteria checks 3/4
Marker Therapeutics' CEO is Juan Vera, appointed in May 2023, has a tenure of 6.58 years. total yearly compensation is $400.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.49% of the company’s shares, worth $301.92K. The average tenure of the management team and the board of directors is 1.4 years and 6.6 years respectively.
Key information
Juan Vera
Chief executive officer
US$400.0k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 2yrs |
| CEO ownership | 2.5% |
| Management average tenure | 1.4yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04
Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$13m |
| Dec 31 2024 | US$400k | US$400k | -US$11m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | US$585k | US$399k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$582k | US$380k | -US$20m |
Compensation vs Market: Juan's total compensation ($USD400.00K) is below average for companies of similar size in the US market ($USD659.32K).
Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.
CEO
Juan Vera (44 yo)
2yrs
Tenure
US$400,000
Compensation
Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023 and serves as its Secretary and Treasurer. He has held various positions at the Center f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2yrs | US$400.00k | 2.49% $ 301.9k | |
| Director of Administration | 8.7yrs | no data | no data | |
| Director of Corporate Operations & External Communications | 1.4yrs | no data | no data | |
| Vice President of Human Resources | 2.3yrs | no data | no data | |
| Head of Clinical Operations | 1.3yrs | no data | no data | |
| Head of Regulatory Affairs | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior Director of Molecular Biology & Virology | no data | no data | no data |
1.4yrs
Average Tenure
54.5yo
Average Age
Experienced Management: MRKR's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.6yrs | US$400.00k | 2.49% $ 301.9k | |
| Independent Director | 5.8yrs | US$52.50k | 0.028% $ 3.4k | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Chairman | 6.6yrs | US$99.00k | 0.034% $ 4.2k | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Director | 3.4yrs | US$60.50k | 0.0014% $ 169.4 |
6.6yrs
Average Tenure
61yo
Average Age
Experienced Board: MRKR's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 03:20 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marker Therapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| John Newman | Canaccord Genuity |
| Yun Zhong | Janney Montgomery Scott LLC |